RZLT

MKT CAP:$296M

Rezolute, Inc.

Market Cap

$296M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.11+$0.94 (+43.32%)

Apr 23, 2026

Company Details

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human mono...

CEO

Nevan Charles Elam

IPO Date

Jan 14, 2013

Website

www.rezolutebio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$84M

EPS (Diluted)

-$0.93

Free Cash Flow

-$77M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q3 2026

May 12, 2026

PENDING

Q2 2026

Feb 12, 2026

$0EPS -$0.22

Q1 2026

Nov 6, 2025

$0EPS -$0.18

FY 2025

Sep 17, 2025

$0EPS -$0.98

Q4 2025

Sep 17, 2025

$0EPS -$0.26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 22	$0	$0	-$11M
Q4 22	$0	$0	-$11M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$14M
Q3 23	$0	$0	-$17M
Q4 23	$0	$0	-$14M
Q1 24	$0	$0	-$16M
Q2 24	$0	-$10.0K	-$15M
Q3 24	$0	-$9.0K	-$16M
Q4 24	$0	$0	-$23M
Q1 25	$0	$0	-$17M
Q2 25	$0	$0	-$17M
Q3 25	$0	$0	-$20M
Q4 25	$0	$0	-$26M
Q1 26	$0	-$8.0K	-$20M
Q2 26	$0	-$7.0K	-$24M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 22	-$14M	-$14M
Q4 22	-$12M	-$12M
Q1 23	-$8M	-$8M
Q2 23	-$7M	-$8M
Q3 23	-$18M	-$18M
Q4 23	-$11M	-$11M
Q1 24	-$11M	-$11M
Q2 24	-$13M	-$13M
Q3 24	-$15M	-$15M
Q4 24	-$19M	-$19M
Q1 25	-$16M	-$16M
Q2 25	-$14M	-$14M
Q3 25	-$17M	-$17M
Q4 25	-$22M	-$22M
Q1 26	-$17M	-$17M
Q2 26	-$20M	-$20M

Capital Expenditures

Quarter	CapEx
Q3 22	$0
Q4 22	$0
Q1 23	$70.0K
Q2 23	$83.0K
Q3 23	$0
Q4 23	$153.0K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0
Q1 26	$0
Q2 26	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	—	+96.1%
Q4 22	—	+70.3%
Q1 23	—	+33.7%
Q2 23	—	+18.5%
Q3 23	—	+59.4%
Q4 23	—	+26.0%
Q1 24	—	+55.7%
Q2 24	—	+5.6%
Q3 24	—	-5.4%
Q4 24	—	+62.3%
Q1 25	—	+6.5%
Q2 25	—	+12.4%
Q3 25	—	+23.5%
Q4 25	—	+11.9%
Q1 26	—	+17.0%
Q2 26	—	+41.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 22	$850.0K	—
Q4 22	$984.0K	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$1M	—
Q2 25	$1M	—
Q3 25	$2M	—
Q4 25	$2M	—
Q1 26	$3M	—
Q2 26	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q3 22	$9M	$2M	—
Q4 22	$9M	$3M	—
Q1 23	$8M	$3M	—
Q2 23	$11M	$3M	—
Q3 23	$14M	$3M	—
Q4 23	$11M	$3M	—
Q1 24	$12M	$4M	—
Q2 24	$12M	$3M	—
Q3 24	$12M	$4M	—
Q4 24	$19M	$4M	—
Q1 25	$13M	$4M	—
Q2 25	$13M	$4M	—
Q3 25	$15M	$5M	—
Q4 25	$21M	$5M	—
Q1 26	$13M	$7M	$167.0K
Q2 26	$14M	$10M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$63M	$0	$63M
Q4 22	$150M	$0	$150M
Q1 23	$154M	$0	$154M
Q2 23	$147M	$0	$147M
Q3 23	$34M	$69M	$103M
Q4 23	$16M	$86M	$102M
Q1 24	$8M	$91M	$99M
Q2 24	$13M	$80M	$93M
Q3 24	$6M	$74M	$80M
Q4 24	$70M	$56M	$127M
Q1 25	$10M	$98M	$108M
Q2 25	$9M	$88M	$97M
Q3 25	$15M	$72M	$87M
Q4 25	$94M	$74M	$168M
Q1 26	$9M	$143M	$152M
Q2 26	$12M	$121M	$133M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 22	17M	+9.8%	+106.2%
Q4 22	34M	+95.0%	+302.1%
Q1 23	51M	+50.5%	+493.5%
Q2 23	51M	+1.7%	+227.9%
Q3 23	51M	-0.0%	+198.6%
Q4 23	51M	+0.0%	+53.1%
Q1 24	51M	-0.0%	+1.7%
Q2 24	51M	-0.0%	-0.0%
Q3 24	51M	-1.2%	-1.2%
Q4 24	51M	0.0%	-1.2%
Q1 25	70M	+37.2%	+35.6%
Q2 25	70M	+0.3%	+36.0%
Q3 25	70M	+0.1%	+37.8%
Q4 25	94M	+34.7%	+85.7%
Q1 26	103M	+9.6%	+48.3%
Q2 26	104M	+0.3%	+48.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 22	$0	26
Q4 22	$0	42
Q1 23	$0	42
Q2 23	$0	42
Q3 23	$0	42
Q4 23	$0	51
Q1 24	$0	51
Q2 24	$0	51
Q3 24	$0	51
Q4 24	$0	59
Q1 25	$0	59
Q2 25	$0	59
Q3 25	$0	59
Q4 25	$0	71
Q1 26	$0	71
Q2 26	$0	71

Revenue / Employee